Get all your news in one place.
100's of premium titles.
One app.
Start reading
Fortune
Fortune
Nick Lichtenberg

Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients

Ozempic (Credit: Getty Images)

Novo Nordisk has announced a sweeping reduction in the cost of its blockbuster diabetes drug Ozempic, cutting the monthly price for cash-paying U.S. patients with Type 2 diabetes from its previous list price of nearly $1,000 to just $499. The news follows mounting calls for greater drug affordability and may signal a pivotal shift in the pharmaceutical pricing landscape.

Details of the price cut

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.